New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
09:48 EDTNYMXNymox reports NX-1207 Phase 2 treatment 'positive' results
Nymox Pharmaceutical reported "positive" new study findings showing that the company's NX-1207 Phase 2 treatment for localized low-risk prostate cancer did not affect testosterone levels in treated men. Analysis of testosterone levels post-treatment for men treated with NX-1207 2.5 mg or 15 mg showed no statistically significant change as compared to control active surveillance patients. This data is consistent with the large body of existing data for men treated with NX-1207 showing a favorable sexual profile for the treatment. One of the major problems with current prostate treatments for localized prostate cancer is the relatively high incidence of reported sexual dysfunction post-treatment. In now 8 completed studies, NX-1207 treatment has shown to have no significant adverse effect post-treatment on sexual function or testosterone levels.For the NX03-0040 study, previously reported study results showed that patients with NX-1207 treatment had significantly less Gleason grade progression, lower average PSA levels, lower numbers of biopsy cores showing greater malignancy, and lower total volume of more malignant cancer compared to controls.
News For NYMX From The Last 14 Days
Check below for free stories on NYMX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
09:32 EDTNYMXNymox announces positive efficacy results in Phase 3 trial of NX-1207
Nymox announced new positive efficacy data for U.S. Study NX02-0022, the company's repeat injection study of NX-1207 for BPH. Analysis of symptomatic improvement from repeat injection over a 1 to 2 year period showed a mean improvement of 8.2 points in the AUA BPH Symptom Index Score. Evaluation of safety data from this study confirmed that NX-1207 reinjection treatment was well-tolerated by patients, did not impair sexual function, and has not shown any drug-related significant side effects. Participants in the clinical trial consisted of 160 consecutively treated men who had previously completed participation in an NX-1207 trial for BPH and who volunteered for a subsequent open label injection of NX-1207.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use